#USA #Houston #antitrust case #US Anesthesia Partners #FTC settlement

Update on the USAP Antitrust Case

On May 26, 2026, a pivotal order was issued by the United States District Court for the Southern District of Texas regarding the ongoing antitrust case against U.S. Anesthesia Partners (USAP). This ruling places a stay on the Federal Trade Commission's (FTC) case while both parties work on finalizing a proposed settlement agreement. The case, which began in 2023, revolves around allegations that USAP consolidated anesthesia practices and leveraged its monopolistic position to artificially inflate anesthesia pricing, thus violating federal antitrust laws.

The timeline of this case highlights its complexity. Just over three years since its inception, progress is being made towards a resolution. On April 23, 2026, the FTC and USAP jointly announced they had reached a preliminary agreement aimed at settling the ongoing litigation and restoring competition in Texas's anesthesia market. However, details regarding the terms of this agreement remain confidential as USAP is expected to implement the proposed relief over the next 180 days. Any outcome will still require the approval of both the FTC and the court to become final.

Simultaneously, a parallel private litigation continues against USAP, with Texas residents seeking damages and other remedies due to inflated anesthesia costs. This class action suit, known as Burbage v. USAP, is led by Christy Burbage, a Texas resident who represents a proposed class of patients who allegedly overpaid for anesthesia services as a direct consequence of USAP's monopolization tactics. Burbage's claims assert that USAP engaged in a systematic acquisition scheme that allowed the company to monopolize the hospital-based anesthesia market while attempting to extend that monopoly into outpatient surgical centers and other similar facilities.

The allegations specify that USAP's monopolization has significantly driven up the prices patients must pay for anesthesia in Texas. Affected class members are increasingly pressing for monetary damages to compensate for these overcharges. As it stands, the court has yet to set a specific date for class certification proceedings, with discussions anticipated in late 2026 or early 2027. Presently, trial proceedings are scheduled for January 2028, indicating that despite a proposed settlement, the litigation process is far from over.

The plaintiffs in the class action suit are represented by a coalition of lawyers from various law firms, including Gibbs Bruns LLP and Shinder Cantor Lerner LLP, amongst others. These legal teams are dedicated to ensuring that the rights of Texas residents are upheld as the situation develops.

In light of these developments, USAP faces not only potential regulatory action but also significant civil liability stemming from the class action. This dual threat underscores the serious ramifications of alleged anti-competitive behavior in sensitive sectors like healthcare, where consumers are vulnerable to exploitation through inflated pricing.

As the case progresses, it highlights the ongoing scrutiny of monopolistic practices within the healthcare industry and the importance of regulatory oversight in maintaining fair competition. The implications for both USAP and its customers are significant, and stakeholders will be watching closely as this situation unfolds in the months to come.

For further inquiries or detailed updates on this case, parties are encouraged to reach out to Gibbs Bruns LLP, a firm specializing in complex commercial litigation. Their involvement signifies the high stakes and potential for precedent-setting outcomes in the realm of antitrust law within healthcare services.